Denali Therapeutics Inc. Other Current Liabilities
Denali Therapeutics Inc. (DNLI) had Other Current Liabilities of $0 as of 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2024-02-28
- 2023-12-31: Other Liabilities, Current $0.00.
- 2022-12-31: Other Liabilities, Current $4.39M; Other Liabilities, Current as first filed $66.69M.
- 2021-12-31: Other Liabilities, Current $53.16M.
- 2020-12-31: Other Liabilities, Current $47.15M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-28 | |
| 2022-12-31 | $4.39M 10-K · filed 2024-02-28 | $66.69M 10-K · filed 2023-02-27 |
| 2021-12-31 | $53.16M 10-K · filed 2023-02-27 | |
| 2020-12-31 | $47.15M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $24.02M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $3.48M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $2.13M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $1.11M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $19.47M 10-K · filed 2020-02-27 | $380.00K 10-K · filed 2019-03-12 |
| 2018-09-30 | $138.00K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $47.00K 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $63.00K 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $63.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |